PD-L1 Immunohistochemistry Comparability and Their Correlation with Clinical Characteristics in NSCLC

Overview

Journal Anal Cell Pathol (Amst)

Specialties Cell Biology
Oncology
Pathology

Date 2020 Nov 18

PMID 33204603

Citations 5

Authors

Chiao-En Wu

Ching-Fu Chang

Liao Kou-Sheng

Ju Chiang

Shih-Wei Lee

Yu-Chi Chiu

Affiliations

Soon will be listed here.

Abstract

Background: PD-L1 expression is an important predictive factor of response to therapy with immune checkpoint inhibitors (ICIs). This study was designed to retrospectively analyze the concordance of PD-L1 measurements using three different assays (Dako22C3, Dako28-8, and SP142) in NSCLC patients and to find possible predictors of high PD-L1 expression.

Materials And Methods: Data of 144 patients with histologically confirmed NSCLC and available PD-L1 measurements treated at the Taoyuan General Hospital from 2018 to 2019 were retrospectively reviewed in the study. Patients' characteristics, including age, sex, clinical stage (T, N, and M) of NSCLC (AJCC, 8 edition), and EGFR/ALK alterations, were analyzed for association with PD-L1 expression.

Results: Measurements of PD-L1 expression levels with Dako22C3 and Dako28-8 were comparable while SP142 showed lower levels of PD-L1 expression. The overall agreement between Dako22C3 and Dako28-8 was 82.2% and 91.6% for both 1% and 50% TPS cut-offs, respectively. The above findings were confirmed by Cohen's kappa. In addition, we found that PD-L1 expression was significantly associated with advanced N stage but not with T and M stages.

Conclusion: Dako22C3 and Dako28-8 showed comparable results in assessing PD-L1 levels. Future prospective studies are needed to validate these findings. N stage may be a good predictor for PD-L1 expression.

Citing Articles

Progress in understanding the regulatory mechanisms of immune checkpoint proteins PD-1 and PD-L1 expression.

Wu X, Zhu Z, Zhang J, Tian M, Zhao P Clin Transl Oncol. 2025; .

PMID: 39776397 DOI: 10.1007/s12094-024-03835-4.

Which Is More Suitable for First-Line Treatment of Extensive-Stage Small Cell Lung Cancer, PD-L1 Inhibitors Versus PD-1 Inhibitors? A Systematic Review and Network Meta-Analysis.

Liu W, Yu L, Feng Y, Huang S, Hua Y, Peng M Clin Respir J. 2024; 18(7):e13804.

PMID: 39073269 PMC: 11284309. DOI: 10.1111/crj.13804.

The Expression and Prognostic Significance of ICOS in NSCLC Integrated Pan-Cancer and Multi-Omics Analyses.

Chen M, Yan X, Hong B, Xiao Y, Qian Y Int J Med Sci. 2024; 21(5):795-808.

PMID: 38616999 PMC: 11008490. DOI: 10.7150/ijms.93262.

TMSB4X: A novel prognostic marker for non-small cell lung cancer.

Yang Z, Luo J, Zhang M, Zhan M, Bai Y, Yang Y Heliyon. 2023; 9(11):e21505.

PMID: 38027718 PMC: 10663839. DOI: 10.1016/j.heliyon.2023.e21505.

PD-L1: expression regulation.

Zhou Y, Li G, Wang J, Liu M, Wang Z, Song Y Blood Sci. 2023; 5(2):77-91.

PMID: 37228770 PMC: 10205351. DOI: 10.1097/BS9.0000000000000149.

References

McHugh M . Interrater reliability: the kappa statistic. Biochem Med (Zagreb). 2012; 22(3):276-82. PMC: 3900052. View

Herbst R, Baas P, Kim D, Felip E, Perez-Gracia J, Han J . Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet. 2015; 387(10027):1540-1550. DOI: 10.1016/S0140-6736(15)01281-7. View

Reck M, Rodriguez-Abreu D, Robinson A, Hui R, Csoszi T, Fulop A . Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer. N Engl J Med. 2016; 375(19):1823-1833. DOI: 10.1056/NEJMoa1606774. View

Rittmeyer A, Barlesi F, Waterkamp D, Park K, Ciardiello F, von Pawel J . Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial. Lancet. 2016; 389(10066):255-265. PMC: 6886121. DOI: 10.1016/S0140-6736(16)32517-X. View

Roviello G, Corona S, DAngelo A, Rosellini P, Nobili S, Mini E . Immune Checkpoint Inhibitors in Pre-Treated Gastric Cancer Patients: Results from a Literature-Based Meta-Analysis. Int J Mol Sci. 2020; 21(2). PMC: 7013524. DOI: 10.3390/ijms21020448. View

Borghaei H, Paz-Ares L, Horn L, Spigel D, Steins M, Ready N . Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer. N Engl J Med. 2015; 373(17):1627-39. PMC: 5705936. DOI: 10.1056/NEJMoa1507643. View

Cao L, Wang X, Li S, Zhi Q, Wang Y, Wang L . PD-L1 is a Prognostic Biomarker in Resected NSCLC Patients with Moderate/high Smoking History and Elevated Serum SCCA Level. J Cancer. 2017; 8(16):3251-3260. PMC: 5665041. DOI: 10.7150/jca.21118. View

Fehrenbacher L, Spira A, Ballinger M, Kowanetz M, Vansteenkiste J, Mazieres J . Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial. Lancet. 2016; 387(10030):1837-46. DOI: 10.1016/S0140-6736(16)00587-0. View

Tsao M, Kerr K, Kockx M, Beasley M, Borczuk A, Botling J . PD-L1 Immunohistochemistry Comparability Study in Real-Life Clinical Samples: Results of Blueprint Phase 2 Project. J Thorac Oncol. 2018; 13(9):1302-1311. PMC: 8386299. DOI: 10.1016/j.jtho.2018.05.013. View

10.

Hsu P, Wang C, Kuo S, Lin S, Lo Y, Huang A . The Co-Expression of Programmed Death-Ligand 1 (PD-L1) in Untreated EGFR-Mutated Metastatic Lung Adenocarcinoma. Biomedicines. 2020; 8(2). PMC: 7167989. DOI: 10.3390/biomedicines8020036. View

11.

Brahmer J, Reckamp K, Baas P, Crino L, Eberhardt W, Poddubskaya E . Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer. N Engl J Med. 2015; 373(2):123-35. PMC: 4681400. DOI: 10.1056/NEJMoa1504627. View

12.

Mok T, Wu Y, Kudaba I, Kowalski D, Cho B, Turna H . Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial. Lancet. 2019; 393(10183):1819-1830. DOI: 10.1016/S0140-6736(18)32409-7. View

13.

Wu J, Sun W, Wang H, Huang X, Wang X, Jiang W . The correlation and overlaps between PD-L1 expression and classical genomic aberrations in Chinese lung adenocarcinoma patients: a single center case series. Cancer Biol Med. 2020; 16(4):811-821. PMC: 6936243. DOI: 10.20892/j.issn.2095-3941.2019.0209. View

14.

Socinski M, Jotte R, Cappuzzo F, Orlandi F, Stroyakovskiy D, Nogami N . Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC. N Engl J Med. 2018; 378(24):2288-2301. DOI: 10.1056/NEJMoa1716948. View

15.

Horn L, Spigel D, Vokes E, Holgado E, Ready N, Steins M . Nivolumab Versus Docetaxel in Previously Treated Patients With Advanced Non-Small-Cell Lung Cancer: Two-Year Outcomes From Two Randomized, Open-Label, Phase III Trials (CheckMate 017 and CheckMate 057). J Clin Oncol. 2017; 35(35):3924-3933. PMC: 6075826. DOI: 10.1200/JCO.2017.74.3062. View

16.

Su S, Dong Z, Xie Z, Yan L, Li Y, Su J . Strong Programmed Death Ligand 1 Expression Predicts Poor Response and De Novo Resistance to EGFR Tyrosine Kinase Inhibitors Among NSCLC Patients With EGFR Mutation. J Thorac Oncol. 2018; 13(11):1668-1675. DOI: 10.1016/j.jtho.2018.07.016. View

17.

Horn L, Gettinger S, Gordon M, Herbst R, Gandhi L, Felip E . Safety and clinical activity of atezolizumab monotherapy in metastatic non-small-cell lung cancer: final results from a phase I study. Eur J Cancer. 2018; 101:201-209. DOI: 10.1016/j.ejca.2018.06.031. View

18.

Herbst R, Soria J, Kowanetz M, Fine G, Hamid O, Gordon M . Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature. 2014; 515(7528):563-7. PMC: 4836193. DOI: 10.1038/nature14011. View

19.

Yoneshima Y, Ijichi K, Anai S, Ota K, Otsubo K, Iwama E . PD-L1 expression in lung adenocarcinoma harboring EGFR mutations or ALK rearrangements. Lung Cancer. 2018; 118:36-40. DOI: 10.1016/j.lungcan.2018.01.024. View

20.

Buttner R, Gosney J, Skov B, Adam J, Motoi N, Bloom K . Programmed Death-Ligand 1 Immunohistochemistry Testing: A Review of Analytical Assays and Clinical Implementation in Non-Small-Cell Lung Cancer. J Clin Oncol. 2017; 35(34):3867-3876. DOI: 10.1200/JCO.2017.74.7642. View